30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
Our findings support a broader interpretation of TBK1-associated neurodegeneration and highlight the importance of multimodal diagnostic approaches that integrate molecular, genetic, imaging, and neuropathological tools. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Tau, mainly expressed in neurons and less expressed in glial cells (astrocytes and oligodendrocytes) and peripheral tissues, is involved in the assembly and stabilization of microtubules, and other biological processes such as axonal transport, metal ion transport, etc. Dysfunction of tau, caused by mutations, hyperphosphorylation, aggregation, or reduced expression, is closely associated with tauopathies (e.g., Alzheimer disease) and psychiatric disorders. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is a neurodegenerative disease, representing the seventh cause of death worldwide and the first cause of dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Aging is the greatest risk factor for learning and memory disorders; dementia prevalence significantly increases with age due to numerous molecular changes in the body. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Herpes simplex virus type 1 (HSV-1) is a continuous health challenge, and current antiviral treatments cannot cure the virus. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Fifteen papers were included. Studies focused on educational and system change to improve the care of people with DSD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
26% of the participants experienced delirium prior to diagnosis of DLB, with one participant experiencing multiple episodes in the 24 months before diagnosis. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia, especially Alzheimer’s disease, is increasing due to population ageing and is projected to nearly triple by 2050. 2 key findings →
Participants: 46 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A longstanding body of public enquiries and research identifies people living with dementia experience systemic inequalities within hospital settings, concluding a focus on improving care cultures is required. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
1508 articles were retrieved and screened using pre-established inclusion criteria; 21 empirical articles were retained. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Improving early detection, management, and treatment of comorbid conditions to dementia in residential care could slow down cognitive and functional decline, and increase residents' quality of life. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of the 74 patients examined, 19 (25.7%) experienced delirium, while 55 (74.3%) showed no symptoms of delirium. 5 key findings →
Participants: 74 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Four GPs and eleven physicians were interviewed, and four major themes emerged: (1) knowledge of best practices of BPSD management, (2) awareness of current challenges in BPSD management, (3) non-involvement, blame shifting and rationalisation: perceived reasons for the current challenges and (4) suggested solutions. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Enrollment of participants began on April 23, 2023. 5 key findings →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Catatonia is a severe and potentially life-threatening but often reversible neuropsychiatric syndrome. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cerebral small vessel disease (CSVD) is a common disease in older people, characterized by damage to intracranial microvessels, leading to cognitive decline, increased risk of stroke, and dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
NCs/CSVD-CN: AUC =0.900, 95% CI: 0.847-0.952. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
With elevated HbA1c, greater LA-derived diol/epoxide ratios were associated with greater WMH volume (β [95% CI] = 0.565 [0.100, 1.030], p = 0.017), lower global BPF (β [95% CI] = -0.476 [-0.903, -0.048], p = 0.029), and poorer memory performance (β [95% CI] = -0.603 [-1.070, -0.136], p = 0.012), such that detrimental associations were observed only in T2DM. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Autosomal dominant Alzheimer disease (ADAD) is caused by pathogenic variants in the APP, PSEN1 and PSEN2 genes, but a substantial fraction of reported variants is of unknown clinical significance. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Age was similar between groups (p = 0.07). 5 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We found that COVID patients initially experienced substantially longer hospital stays (8.3 vs 4.6 days) and higher 30-day mortality (34% vs 5%) compared to patients without COVID. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
These findings highlight potential access and quality-of-care issues in PR, with implications for Medicare Advantage benchmarks. 4 key findings →
Participants: 4,965 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Participants racialized as Black living in a county with a history of lynching, disproportionate police killings, and disproportionate jail and prison incarceration were 2.8 (95%CI [-0.003, 5.834]) times more likely to have at least one incident of cognitive impairment between 2008-2020 compared to participants racialized as Black living in a county with a history of lynching and disproportionate police killings but not disproportionate incarceration. 3 key findings →
Participants: 185 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The current study provides opportunities for safer approaches that using compounds derived from plants and links it to nanotechnology, could be used in the pharmaceutical industry to treat Alzheimer’s disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
H]UCB-J was found to be reduced in frontal cortex from patients with AD. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events